Currently, the standard treatment of T cell acute lymphoblastic leukemia (T-ALL) patients is intensive chemotherapy with almost 70% 5-year event free survival for pediatric and 50% for adult T-ALL patients. Moreover, such non-targeted therapies fail to address high-risk T-ALL subtypes. Unfortunately, recent attempts to introduce targeted therapies were plagued by both toxicity and resistance, further underlining the urgency for new treatments that also deal with leukemia-initiating cells (LIC) leading to complete disease remission. During the last funding period we were able to make important steps towards the understanding of the role of the ubiquitin system in acute lymphoblastic leukemia (ALL). We were able to identify somatic mutations on Fbw7, a ubiquitin ligase, in a large fraction of T cell ALL patients. We were able to show that Fbw7 can ubiquitinate and degrade NOTCH1 and MYC, two of the most important oncogenes in T-ALL. Using conditional Fbw7 alleles and were able to prove in vivo its role as a tumor suppressor. More recently we generated animals that expressed the exact Fbw7 mutations found in T-ALL patients and we were able to show that such missense mutations are able to directly expand leukemia initiating cells (LIC) but at the same time space normal hematopoiesis, providing an explanation on the selection of such mutations in this disease. Further analysis has shown that Fbw7 mutations expand LIC by aberrantly increasing the half-life of MYC. Moreover, conditional MYC deletions lead to LIC targeting and complete disease eradication opening the way for therapeutic targeting of T-ALL """"""""stem"""""""" cells. Indeed, preliminary studies described here show that bromodomain and extra-terminal (BET) inhibitors can efficiently target MYC transcription and lead to suppression of growth in human T-ALL lines and primary cells. In this renewal application we would like to take advantage of all these significant developments and take our studies all the way from basic understanding of leukemia stem cell biology and the impact of FBW7 mutations to the identification of novel drugs that can target initiation and progression of this devastating tumor that frequently afflicts children and adolescents.

Public Health Relevance

T cell acute lymphoblastic leukemia is a devastating blood tumor afflicting both children and adults. Currently there are no targeted therapies. In this grant we identify the FBW7 ligase as a tumor suppressor and study its function in leukemia initiation and progression.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Mccarthy, Susan A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5
Kourtis, Nikos; Lazaris, Charalampos; Hockemeyer, Kathryn et al. (2018) Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nat Med 24:1157-1166
Cimmino, Luisa; Neel, Benjamin G; Aifantis, Iannis (2018) Vitamin C in Stem Cell Reprogramming and Cancer. Trends Cell Biol 28:698-708
Cimmino, Luisa; Dolgalev, Igor; Wang, Yubao et al. (2017) Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell 170:1079-1095.e20
Cimmino, Luisa; Aifantis, Iannis (2017) Alternative roles for oxidized mCs and TETs. Curr Opin Genet Dev 42:1-7
Valls, Ester; Lobry, Camille; Geng, Huimin et al. (2017) BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discov 7:506-521
Aranda-Orgilles, Beatriz; SaldaƱa-Meyer, Ricardo; Wang, Eric et al. (2016) MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis. Cell Stem Cell 19:784-799
Ntziachristos, Panagiotis; Abdel-Wahab, Omar; Aifantis, Iannis (2016) Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol 17:1016-24
Strikoudis, Alexandros; Lazaris, Charalampos; Trimarchi, Thomas et al. (2016) Regulation of transcriptional elongation in pluripotency and cell differentiation by the PHD-finger protein Phf5a. Nat Cell Biol 18:1127-1138
Guillamot, Maria; Cimmino, Luisa; Aifantis, Iannis (2016) The Impact of DNA Methylation in Hematopoietic Malignancies. Trends Cancer 2:70-83

Showing the most recent 10 out of 60 publications